Roque, ValentinJessop, MaryamPereira, LuisaGape, PaulDizdarevic, SabinaSousa, EvaCarolino, Elisabete2019-06-212019-06-212019-06Roque V, Jessop M, Pereira L, Gape P, Sousa E, Carolino E, et al. Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response. Nucl Med Commun. 2019;40(6):588-96.http://hdl.handle.net/10400.21/10177This work aims to assess whether the biochemical response of radium-223-dichloride treatment can be predicted based on the pretherapy bone scan, and consequently, if bone scan index (BSI) and maximum lesion intensity have a place as alternatives or as complements to extent of bone disease (EOBD) scoring in predicting biochemical response to treatment. Many cases of advanced prostate cancer have evidence of bone metastasis. Accurate EOBD quantification could help predict the response to radium-223-dichloride therapy. Current EOBD score is simple to use but does not consider size, intensity or localization of lesion BSI might be more suitable for stratification of bone metastases. Patients and methods: Bone scans (n=20) preceding radium-223-dichloride treatment for prostate cancer were assessed retrospectively using automated BSI software (EXINI) and by assessing maximum counts per lesion. Results were then compared to total alkaline phosphatase (ALP) as a measure of biochemical response to therapy using linear regressions and to their EOBD scores using box plot analysis. Results: Moderate correlation was found between ALP response and maximum lesion intensity (R2=0.41) and BSI (R2=0.46). A strong correlation (R2=0.71) was found between baseline ALP and BSI and between lesion number and BSI (R2=0.60). Visual assessment of EOBD score was found to correlate well with baseline ALP and maximum ALP response. Conclusion: BSI is a useful asset in the stratification of patients with metastatic bone disease. It may also have a place in the prediction of biochemical response.engAlkaline phosphataseBone neoplasmsBone and bonesHumansMaleProstatic neoplasmsRadioisotopesRadiumRetrospective studiesTreatment outcomeProstate cancerjournal article10.1097/MNM.0000000000001005